Scandion Oncology (Sweden) Investor Sentiment

SCOL Stock  SEK 0.06  0.01  9.70%   
Slightly above 62% of Scandion Oncology's investor base is looking to short. The analysis of current outlook of investing in Scandion Oncology AS suggests that many traders are alarmed regarding Scandion Oncology's prospects. Scandion Oncology's investing sentiment can be driven by a variety of factors including economic data, Scandion Oncology's earnings reports, geopolitical events, and overall market trends.
  
over six months ago at news.google.com         
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial - Ma...
Google News at Macroaxis
over six months ago at news.google.com         
Scandion Oncology Q4 2023 - Striving towards randomised controlled data - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Scandion Oncology Q4 yearend report 2023 -February 28, 2024 at 0101 am EST - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Invitation to Scandion Oncology webcast and conference call February 28, 2024 - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Transcript Scandion Oncology AS - Special Call -February 05, 2024 at 0800 am EST - Marketscreener.co...
Google News at Macroaxis
over a year ago at news.google.com         
Breakeven Is Near for Scandion Oncology AS - Simply Wall St
Google News at Macroaxis
over a year ago at news.google.com         
Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial - Marketscree...
Google News at Macroaxis
over a year ago at news.google.com         
Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-10...
Google News at Macroaxis
over a year ago at news.google.com         
CORIST part 3 topline data are expected in the second half of January 2024 - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors - Yahoo...
Google News at Macroaxis
over a year ago at news.google.com         
Scandion Oncology identifies potentially effective treatment of gastric cancer - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Scandion Oncology Obtains Patent for Combination Cancer ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Scandion Oncology is granted new Composition of Matter-patent on ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Scandions CMO Our overall survival data are quite impressive - BioStock - Connecting Innovation and ...
Google News at Macroaxis
over a year ago at news.google.com         
Transcript Scandion Oncology AS, Nine Months 2023 Earnings Call, Nov 22, 2023 - Marketscreener.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Scandion Oncology that are available to investors today. That information is available publicly through Scandion media outlets and privately through word of mouth or via Scandion internal channels. However, regardless of the origin, that massive amount of Scandion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Scandion Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Scandion Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Scandion Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Scandion Oncology alpha.

Scandion Oncology Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for Scandion Stock Analysis

When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.